| Non-Small Cell Lung Carcinoma
Augtyro vs Krazati
Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.Deep comparison between: Augtyro vs Krazati with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsKrazati has a higher rate of injection site reactions vs Augtyro based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Krazati but not Augtyro, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Augtyro
Krazati
At A Glance
Oral
Once daily x14 days, then twice daily
ROS1/TRK inhibitor
Oral
Twice daily
KRAS G12C inhibitor
Indications
- Non-Small Cell Lung Carcinoma
- Solid Neoplasm
- Non-Small Cell Lung Carcinoma
- Colorectal Neoplasms
Dosing
Non-Small Cell Lung Carcinoma, Solid Neoplasm 160 mg orally once daily for 14 days, then increase to 160 mg twice daily, with or without food, until disease progression or unacceptable toxicity.
Non-Small Cell Lung Carcinoma 600 mg orally twice daily as a single agent until disease progression or unacceptable toxicity; swallow tablets whole with or without food.
Colorectal Neoplasms 600 mg orally twice daily in combination with cetuximab until disease progression or unacceptable toxicity; swallow tablets whole with or without food.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Dizziness, dysgeusia, peripheral neuropathy, constipation, dyspnea, fatigue, ataxia, cognitive impairment, muscular weakness, nausea.
Serious Pneumonia, dyspnea, pleural effusion, hypoxia.
Most common (>=25%) nausea, diarrhea, vomiting, fatigue, musculoskeletal pain, hepatotoxicity, renal impairment, edema, dyspnea, decreased appetite
Serious pneumonia, dyspnea, renal impairment, sepsis, respiratory failure, pleural effusion, anemia, cardiac failure
Pharmacology
Repotrectinib is a kinase inhibitor of ROS1 and tropomyosin receptor tyrosine kinases (TRKA, TRKB, TRKC); fusion proteins containing these domains drive tumorigenic potential through hyperactivation of downstream signaling pathways leading to unconstrained cell proliferation.
Adagrasib is an irreversible KRAS G12C inhibitor that covalently binds to the mutant cysteine residue, locking KRAS G12C in its inactive GDP-bound state and preventing downstream signaling without affecting wild-type KRAS.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Augtyro
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Krazati
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Augtyro
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Krazati
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Augtyro
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Krazati
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Augtyro.
No savings programs available for Krazati.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AugtyroView full Augtyro profile
KrazatiView full Krazati profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.